ombitasvir + paritaprevir + ritonavir + sofosbuvir

A combination of four direct-acting antiviral agents, **ombitasvir**, **paritaprevir**, **ritonavir**, and **sofosbuvir**. Each of these drugs targets the hepatitis C virus (HCV) at different stages: - Ombitasvir is an HCV **NS5A inhibitor**. - Paritaprevir is an HCV **NS3/4A protease inhibitor**. - Ritonavir acts as a **CYP3A inhibitor** used to boost paritaprevir exposure. - Sofosbuvir is an HCV **NS5B polymerase inhibitor**. This specific four-drug combination does *not* correspond to an approved branded regimen (as dasabuvir, not sofosbuvir, is used in the marketed Viekira Pak product). Theoretically, the combined use aims to provide pan-genotypic, potent suppression of HCV replication via **complementary mechanisms**. Primary indication would be chronic HCV infection, including patients with or without cirrhosis, although no marketed product or clinical guideline recommends this exact four-drug combination.